9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Authors
Keywords
-
Journal
DIABETES CARE
Volume 46, Issue Supplement_1, Pages S140-S157
Publisher
American Diabetes Association
Online
2022-12-12
DOI
10.2337/dc23-s009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETES CARE
- RESULTS OF A 24-WEEK TRIAL OF TECHNOSPHERE INSULIN VERSUS INSULIN ASPART IN TYPE 2 DIABETES
- (2021) Byron J. Hoogwerf et al. Endocrine Practice
- Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis
- (2021) Apostolos Tsapas et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
- (2021) Marshall Grant et al. CLINICAL PHARMACOKINETICS
- The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2021) Richard I.G. Holt et al. DIABETES CARE
- Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
- (2021) Ildiko Lingvay et al. LANCET
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
- (2020) Apostolos Tsapas et al. ANNALS OF INTERNAL MEDICINE
- Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
- (2020) Thomas Blevins et al. DIABETES CARE
- Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study
- (2020) Leslie Klaff et al. DIABETES OBESITY & METABOLISM
- International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors
- (2019) Thomas Danne et al. DIABETES CARE
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
- (2019) Richard Pratley et al. LANCET
- Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes
- (2019) Zoltán Taybani et al. Diabetes Therapy
- Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
- (2019) David R Matthews et al. LANCET
- Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
- (2019) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
- (2019) Sue A. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
- (2019) Jennifer R. Snaith et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- The Cost of Diabetes Care—An Elephant in the Room
- (2018) Matthew C. Riddle et al. DIABETES CARE
- Insulin Access and Affordability Working Group: Conclusions and Recommendations
- (2018) William T. Cefalu et al. DIABETES CARE
- Cost-related medication non-adherence among U.S. adults with diabetes
- (2018) Hyojung Kang et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effect of metformin on glycaemic control in patients with type 1 diabetes: A meta-analysis of randomized controlled trials
- (2018) Haiyang Meng et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes
- (2018) Kasia J. Lipska et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3 year trial
- (2018) Mattijs Out et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
- (2018) Halis Kaan Akturk et al. Diabetes Technology & Therapeutics
- A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses
- (2018) Alan Maloney et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
- (2018) Julio Rosenstock et al. DIABETES CARE
- Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
- (2018) Martin Tauschmann et al. LANCET
- Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes
- (2017) Carol Wysham et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes
- (2017) Wendy Lane et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
- (2017) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreas transplantation
- (2017) Patrick G Dean et al. BMJ-British Medical Journal
- Pancreas transplantation
- (2017) Patrick G Dean et al. BMJ-British Medical Journal
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
- (2017) John R Petrie et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
- (2017) Paresh Dandona et al. Lancet Diabetes & Endocrinology
- Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
- (2017) Philip A Levin et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
- (2016) Nisa M. Maruthur et al. ANNALS OF INTERNAL MEDICINE
- Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population
- (2016) DIABETES CARE
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
- (2016) Vanita R. Aroda et al. DIABETES CARE
- Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
- (2016) Bo Ahrén et al. DIABETES CARE
- Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
- (2016) Avivit Cahn et al. DIABETES CARE
- Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
- (2016) Chantal Mathieu et al. DIABETES CARE
- Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis
- (2016) Sonal Singh et al. DIABETES OBESITY & METABOLISM
- New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)
- (2016) Y. Terauchi et al. DIABETES OBESITY & METABOLISM
- A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
- (2016) Mirna S. Abd El Aziz et al. DIABETES OBESITY & METABOLISM
- EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U-500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES
- (2016) Carol Wysham et al. Endocrine Practice
- Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes
- (2016) Ildiko Lingvay et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
- (2016) Richard M. Bergenstal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study
- (2016) Vanita R. Aroda et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- New Insulin Delivery Recommendations
- (2016) Anders H. Frid et al. MAYO CLINIC PROCEEDINGS
- Social Determinants of Health, Cost-related Nonadherence, and Cost-reducing Behaviors Among Adults With Diabetes
- (2016) Minal R. Patel et al. MEDICAL CARE
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
- (2015) Francesco Giorgino et al. DIABETES CARE
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
- (2015) Philip D. Home et al. DIABETES CARE
- Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial
- (2015) Bruce W. Bode et al. DIABETES CARE
- Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis
- (2015) Bruce A. Buckingham et al. DIABETES CARE
- Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era
- (2015) Kirstine J. Bell et al. DIABETES CARE
- Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
- (2015) M. A. Abdul-Ghani et al. DIABETES OBESITY & METABOLISM
- One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension
- (2015) M. C. Riddle et al. DIABETES OBESITY & METABOLISM
- Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensi
- (2015) H. Yki-Järvinen et al. DIABETES OBESITY & METABOLISM
- New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
- (2015) G. B. Bolli et al. DIABETES OBESITY & METABOLISM
- Safety and Efficacy of Insulin Therapy Delivered via a 4mm Pen Needle in Obese Patients With Diabetes
- (2015) Richard M. Bergenstal et al. MAYO CLINIC PROCEEDINGS
- Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes
- (2014) Francesca Porcellati et al. DIABETES CARE
- Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
- (2014) Jane L. Chiang et al. DIABETES CARE
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
- (2014) Hannele Yki-Järvinen et al. DIABETES CARE
- Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
- (2014) Michaela Diamant et al. DIABETES CARE
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
- (2014) Conrad Eng et al. LANCET
- Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis
- (2014) A. C. Tricco et al. BMJ-British Medical Journal
- Effect of Patients’ Risks and Preferences on Health Gains With Plasma Glucose Level Lowering in Type 2 Diabetes Mellitus
- (2014) Sandeep Vijan et al. JAMA Internal Medicine
- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
- (2013) Wendy L. Bennett et al. ANNALS OF INTERNAL MEDICINE
- Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus
- (2013) Hsin-Chieh Yeh et al. ANNALS OF INTERNAL MEDICINE
- Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis
- (2013) O. J. Phung et al. DIABETES OBESITY & METABOLISM
- Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial
- (2013) H. W. Rodbard et al. DIABETIC MEDICINE
- Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
- (2013) Richard M. Bergenstal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus (在基础-餐时糖尿病治疗方案中使用门冬胰岛素与使用常规人胰岛素对照研究的Meta分析)
- (2013) Simon Heller et al. Journal of Diabetes
- Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial
- (2013) Helena W Rodbard et al. Lancet Diabetes & Endocrinology
- Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis
- (2013) Kirstine J Bell et al. Lancet Diabetes & Endocrinology
- Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
- (2012) M. Davies et al. DIABETES CARE
- Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
- (2012) B. Zinman et al. DIABETES CARE
- Insulin Therapy and Hypoglycemia
- (2012) Anthony L. McCall ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
- (2012) R. R. Henry et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
- (2010) Z. Wang et al. DIABETES CARE
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
- (2009) S. R. Singh et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATETMstudy
- (2009) L. Blonde et al. DIABETES OBESITY & METABOLISM
- Safe and Simple Emergency Department Discharge Therapy for Patients with Type 2 Diabetes Mellitus and Severe Hyperglycemia
- (2009) Ambika Babu et al. Endocrine Practice
- Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
- (2008) E. Mannucci et al. DIABETES OBESITY & METABOLISM
- Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
- (2008) Matteo Monami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial
- (2008) P. C. Bartley et al. DIABETIC MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started